<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35172656</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2167-9223</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>7-8</Issue><PubDate><Year>2022</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Amyotrophic lateral sclerosis &amp; frontotemporal degeneration</Title><ISOAbbreviation>Amyotroph Lateral Scler Frontotemporal Degener</ISOAbbreviation></Journal><ArticleTitle>Clinical trials in pediatric ALS: a TRICALS feasibility study.</ArticleTitle><Pagination><StartPage>481</StartPage><EndPage>488</EndPage><MedlinePgn>481-488</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21678421.2021.2024856</ELocationID><Abstract><AbstractText><i>Background:</i> Pediatric investigation plans (PIPs) describe how adult drugs can be studied in children. In 2015, PIPs for Amyotrophic Lateral Sclerosis (ALS) became mandatory for European marketing-authorization of adult treatments, unless a waiver is granted by the European Medicines Agency (EMA).<i>Objective:</i> To assess the feasibility of clinical studies on the effect of therapy in children (&lt;18 years) with ALS in Europe.<i>Methods:</i> The EMA database was searched for submitted PIPs in ALS. A questionnaire was sent to 58 European ALS centers to collect the prevalence of pediatric ALS during the past ten years, the recruitment potential for future pediatric trials, and opinions of ALS experts concerning a waiver for ALS.<i>Results:</i> Four PIPs were identified; two were waived and two are planned for the future. In total, 49 (84.5%) centers responded to the questionnaire. The diagnosis of 44,858 patients with ALS was reported by 46 sites; 39 of the patients had an onset &lt; 18 years (prevalence of 0.008 cases per 100,000 or 0.087% of all diagnosed patients). The estimated recruitment potential (47 sites) was 26 pediatric patients within five years. A majority of ALS experts (75.5%) recommend a waiver should apply for ALS due to the low prevalence of pediatric ALS.<i>Conclusions:</i> ALS with an onset before 18 years is extremely rare and may be a distinct entity from adult ALS. Conducting studies on the effect of disease-modifying therapy in pediatric ALS may involve lengthy recruitment periods, high costs, ethical/legal implications, challenges in trial design and limited information.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kliest</LastName><ForeName>Tessa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biostatistics &amp;amp; Research Support, Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, King's College London, Maurice Wohl Clinical Neuroscience Institute, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albanese</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Research Hospital Rozzano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Clinical Sciences, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amador</LastName><ForeName>Maria Del Mar</ForeName><Initials>MDM</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Centre de r&#xe9;f&#xe9;rence SLA Ile de France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Br&#xc5;then</LastName><ForeName>Geir</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Trondheim, Trondheim, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuromedicine and Movement Science, Norwegian University of Science and Technology, Trondheim, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunaud-Danel</LastName><ForeName>Veronique</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>ALS centre, CHU, University of Lille Nord de France, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brylev</LastName><ForeName>Lev</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0003-2314-6523</Identifier><AffiliationInfo><Affiliation>Bujanov Moscow City Clinical Hospital, Moscow, Russian Federation.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Moscow Research and Clinical Center for Neuropsychiatry of the Healthcare Department, Moscow, Russian Federation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camu</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>ALS Centre CHU Gui de Chauliac, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7556-0158</Identifier><AffiliationInfo><Affiliation>Institute of Physiology-Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurosciences and Mental Health, H Santa Maria-CHLN, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cereda</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Regional Newborn Screening Laboratory, Vittore Buzzi Children's Hospital-University of Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cetin</LastName><ForeName>Hakan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaverri</LastName><ForeName>Delia</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Neurology Service, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9579-5341</Identifier><AffiliationInfo><Affiliation>'Rita Levi Montalcini' Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliera Citt&#xe0; della Salute e della Scienza, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>Centre Constitutif SLA, CHRU de Tours - F&#xe9;d&#xe9;ration des centres SLA Tours-Limoges, LitORALS, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Centre Constitutif de reference SLA-F&#xe9;d&#xe9;ration Tours-Limoges, CHU de Limoges, Limoges, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Marchi</LastName><ForeName>Fabiola</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>"Maggiore della Carit&#xe0;" University Hospital, Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desnuelle</LastName><ForeName>Claude</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>H&#xf4;pital Pasteur 2 - CHU de Nice, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Es</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteban</LastName><ForeName>Jes&#xda;s</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>ALS Research Lab - ALS Unit, Instituto de Investigaci&#xf3;n Sanitaria Hospital 12 de Octubre "i&#x2009;+&#x2009;12", CIBERER, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filosto</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2852-7512</Identifier><AffiliationInfo><Affiliation>Department of Clinical and Experimental Sciences, University of Brescia; NeMO-Brescia Clinical Center for Neuromuscular Diseases, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garc&#xcd;a Redondo</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Research Lab - ALS Unit, Instituto de Investigaci&#xf3;n Sanitaria Hospital 12 de Octubre "i&#x2009;+&#x2009;12", CIBERER, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosskreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Precision Neurology, Dept. of Neurology, L&#xfc;beck University Hospital, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanemann</LastName><ForeName>Clemens O</ForeName><Initials>CO</Initials><Identifier Source="ORCID">0000-0002-1951-1025</Identifier><AffiliationInfo><Affiliation>University of Plymouth, Peninsula Schools of Medicine and Dentistry, Plymouth, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holm&#xd8;y</LastName><ForeName>Trygve</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Akershus University Hospital, L&#xf8;renskog, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xd8;yer</LastName><ForeName>Helle</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Medical Genetics, Telemark Hospital, Skien, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ingre</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Neurology, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koritnik</LastName><ForeName>Blaz</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-5083-8261</Identifier><AffiliationInfo><Affiliation>Institute of Clinical Neurophysiology, University Medical Centre Ljubljana, Ljubljana, Slovenia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuzma-Kozakiewicz</LastName><ForeName>Magdalena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University of Warsaw, Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lambert</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, Royal Stoke University Hospital, Stoke, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leigh</LastName><ForeName>Peter N</ForeName><Initials>PN</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Brighton and Sussex Medical School, Trafford Centre for Biomedical Research, University of Sussex, Brighton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lunetta</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>NEMO Clinical Center, Serena Onlus Foundation, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NEMO LAB, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandrioli</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biomedical, Metabolic and Neural Sciences, Center for Neuroscience and Neurotechnology, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuroscience, St. Agostino Estense Hospital, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mcdermott</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-1269-9053</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, University of Sheffield, Sheffield Institute for Translational Neuroscience, Sheffield, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>ALS Outpatient Department, Charit&#xe9; - Universitatsmedizin Berlin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora</LastName><ForeName>Jesus S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>ALS Unit/Neurology, Hospital San Rafael, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>M&#xd3;nica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Functional Unit of Amyotrophic Lateral Sclerosis (UFELA), Service of Neurology, Bellvitge University Hospital, Hospitalet de Llobregat, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reviers</LastName><ForeName>Evy</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>European Organization for Professionals and Patients with ALS (EUpALS) &amp;amp; ALS Liga Belgium, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riva</LastName><ForeName>Nilo</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neurology, Experimental Neuropathology Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roes</LastName><ForeName>Kit C B</ForeName><Initials>KCB</Initials><AffiliationInfo><Affiliation>Department of Health Evidence, Section Biostatistics, Radboud University Medical Centre Nijmegen, Nijmegen, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rubio</LastName><ForeName>Miguel &#xc1;</ForeName><Initials>M&#xc1;</Initials><AffiliationInfo><Affiliation>Neuromuscular Unit, Department of Neurology, Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto Hospital del Mar de Investivaciones M&#xe9;dicas (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salachas</LastName><ForeName>Fran&#xc7;ois</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de Neurologie, Centre de r&#xe9;f&#xe9;rence SLA Ile de France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>H&#xf4;pital de la Piti&#xe9; Salp&#xea;tri&#xe8;re, AP-HP, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarafov</LastName><ForeName>Stayko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinic of General Neurology, Medical University Sofia, University Hospital Alexandrovska, Sofia, Bulgaria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorar&#xd9;</LastName><ForeName>Gianni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neurosciences, University of Padova, Padova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stevic</LastName><ForeName>Zorica</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinic of Neurology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svenstrup</LastName><ForeName>Kirsten</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Bispebjerg-Frederiksberg Hospital and Rigshospitalet, University Hospital of Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xd8;ller</LastName><ForeName>Anette Torvin</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Neurology, Aarhus University Hospital, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Department of Neurosciences, Laboratory for Neurobiology, KU Leuven and Centre for Brain &amp;amp; Disease Research, VIB, Leuven Brain Institute, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Leeuwen</LastName><ForeName>Lucie A G</ForeName><Initials>LAG</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varona</LastName><ForeName>Luis</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Neurology, Basurto University Hospital, Vizcaya, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>V&#xc1;zquez Costa</LastName><ForeName>Juan F</ForeName><Initials>JF</Initials><Identifier Source="ORCID">0000-0002-3043-7938</Identifier><AffiliationInfo><Affiliation>ALS Unit and Neuromuscular Disease Unit, Department of Neurology, Hospital La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuromoscular Disease Unit/ALS Clinic, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Academic Unit of Neurology Trinity College Dublin Ireland, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>02</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Amyotroph Lateral Scler Frontotemporal Degener</MedlineTA><NlmUniqueID>101587185</NlmUniqueID><ISSNLinking>2167-8421</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Pediatric amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">clinical trial</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">ethics</Keyword><Keyword MajorTopicYN="N">pediatric investigation plan</Keyword><Keyword MajorTopicYN="N">therapy</Keyword></KeywordList><CoiStatement>AAC reports consultancies or advisory boards for Amylyx, Apellis, Biogen Idec, Brainstorm, Cytokinetics, GSK, Lilly, Mitsubishi Tanabe Pharma, Novartis, OrionPharma, Quralis, and Wave Pharmaceuticals. CJM has conducted consultancy for Biogen, Merz, Amylyx, Orphazyme and Orion. S.P. received honoraria as a speaker/consultant from Biogen GmbH, Roche, Novartis, Teva, Cytokinetics Inc. and Desitin; and grants from DGM e.V, Federal Ministry of Education and Research, German Israeli Foundation for Scientific Research and Development, EU Joint Programme for Neurodegenerative Disease Research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>2</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>2</Month><Day>17</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35172656</ArticleId><ArticleId IdType="pmc">PMC9662181</ArticleId><ArticleId IdType="doi">10.1080/21678421.2021.2024856</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The European Parliament and The Council of the European Union. Regulation No 1901/2006 of the European Parliament and of the Council on Medicinal Products for Paediatric Use and Amending Regulation. Off J Eur Union 2006;378:1&#x2013;19.</Citation></Reference><Reference><Citation>Sabatelli M, Madia F, Conte A, Luigetti M, Zollino M, Mancuso I, et al. . Natural history of young-adult amyotrophic lateral sclerosis. Neurology 2008;71:876&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">18596241</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouveia LO, de Carvalho M.. Young-onset sporadic amyotrophic lateral sclerosis: a distinct nosological entity? Amyotroph Lateral Scler. 2007;8:323&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">17852021</ArticleId></ArticleIdList></Reference><Reference><Citation>Picher-Martel V, Brunet F, Dupr&#xe9; N, Chrestian N.. The occurrence of FUS mutations in pediatric amyotrophic lateral sclerosis: a case report and review of the literature. J Child Neurol. 2020;35:556&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">32281455</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Burgunder JM.. Recent progress in the genetics of motor neuron disease. Eur J Med Genet. 2014;57:103&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">24503148</ArticleId></ArticleIdList></Reference><Reference><Citation>Logroscino G, Traynor BJ, Hardiman O, Chi&#xf3; A, Mitchell D, Swingler RJ, et al. . Incidence of amyotrophic lateral sclerosis in Europe. J Neurol Neurosurg Psychiatry. 2010;81:385&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2850819</ArticleId><ArticleId IdType="pubmed">19710046</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Barnwell J, Al-Chalabi A, Eisen A.. Young-onset amyotrophic lateral sclerosis: Historical and other observations. Brain. 2012;135:2883&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">22661746</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency . Decision Class Waiver on conditions - granting, review, revocation. 2011. Available at: https://www.ema.europa.eu/en/documents/other/cw/1/2011-ema-decision-19-december-2011-class-waiver-conditions_en.pdf. Accessed December 1, 2020.</Citation></Reference><Reference><Citation>European Medicines Agency . Decision Class Waiver on conditions - granting, review, revocation. 2010. Available at: www.ema.europa.eu/en/documents/other/p/63/2010-ema-decision-20-december-2010-class-waiver-conditions_en.pdf. Accessed December 1, 2020.</Citation></Reference><Reference><Citation>European Medicines Agency . Summary Report on the review of the list of granted Class Waivers (EMA/PDCO/178231/2015EMA/PDCO). 2015;44(0).</Citation></Reference><Reference><Citation>van Eijk RPA, Kliest T, van den Berg LH.. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis. Curr Opin Neurol. 2020;33:655&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">32796282</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Kliest T, McDermott CJ, Roes KCB, Van Damme P, Chio A, et al. . TRICALS: creating a highway toward a cure. Amyotroph Lateral Scler Front Degener 2020;1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">32643415</ArticleId></ArticleIdList></Reference><Reference><Citation>The European Parliament and The Council of the European Union . Guideline on good pharmacovigilance practices (GVP).. 2012;(February):1&#x2013;47. Available at: http://www.jfda.jo/Download/JPC/TheGoodPharmacovigilancePracticev2.pdf. Accessed 1 December 2020.</Citation></Reference><Reference><Citation>Opinion of the Paediatric Committee on the granting of a product-specific waiver EMEA-002403-PIP01-18. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0337/2018-ema-decision-8-october-2018-granting-product-specific-waiver-synthetic-ribonucleic-acid_en.pdf. Accessed August 29, 2020.</Citation></Reference><Reference><Citation>European Medicines Agency . Opinion of the Paediatric Committee on the granting of a product-specific waiver and on the refusal of a product- specific waiver EMEA-001748-PIP02-18. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0317/2018-ema-decision-12-september-2018-granting-product-specific-waiver-arimoclomol-citrate-condition_en.pdf. Accessed August 29, 2020.</Citation></Reference><Reference><Citation>European Medicines Agency . Opinion of the Paediatric Committee on the refusal of a product-specific waiver EMEA-002469-PIP01-18. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0099/2019-ema-decision-22-march-2019-refusal-product-specific-waiver-pyrimidinyl-aminopyridine-dual_en.pdf. Accessed August 29, 2020.</Citation></Reference><Reference><Citation>European Medicines Agency . Opinion of the Paediatric Committee on the granting of a product-specific waiver EMEA-001266-PIP04-19. Available at: https://www.ema.europa.eu/en/documents/pip-decision/p/0001/2020-ema-decision-3-january-2020-granting-product-specific-waiver-masitinib-mesylate-emea-001266_en.pdf. Accessed August 29, 2020.</Citation></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Brayne C, Beghi E, Van Den Berg LH, Chio A, et al. . The changing picture of amyotrophic lateral sclerosis: lessons from European registers. J Neurol Neurosurg Psychiatry. 2017;88:557&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28285264</ArticleId></ArticleIdList></Reference><Reference><Citation>The European Parliament and The Council of the European Union. Clinical trials regulation. Off J Eur Union 2014;2014:55&#x2013;7.</Citation></Reference><Reference><Citation>Jayasundara K, Hollis A, Krahn M, Mamdani M, Hoch JS, Grootendorst P.. Estimating the clinical cost of drug development for orphan versus non-orphan drugs. Orphanet J Rare Dis. 2019;14:12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6327525</ArticleId><ArticleId IdType="pubmed">30630499</ArticleId></ArticleIdList></Reference><Reference><Citation>Berdud M, Drummond M, Towse A.. Establishing a reasonable price for an orphan drug. Cost Eff Resour Alloc. 2020;18:1&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472708</ArticleId><ArticleId IdType="pubmed">32908456</ArticleId></ArticleIdList></Reference><Reference><Citation>Anzelewicz S, Garnier H, Rangaswami A, Czauderna P.. Cultural, geographical and ethical questions when looking to enroll pediatric patients in rare disease clinical trials. Expert Opin Orphan Drugs. 2017;5:613&#x2013;21.</Citation></Reference><Reference><Citation>Day S, Jonker AH, Lau LPL, Hilgers RD, Irony I, Larsson K, et al. . Recommendations for the design of small population clinical trials. Orphanet J Rare Dis. 2018;13:1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219020</ArticleId><ArticleId IdType="pubmed">30400970</ArticleId></ArticleIdList></Reference><Reference><Citation>Hepburn CM, Gilpin A, Autmizguine J, Denburg A, Dupuis LL, Finkelstein Y, et al. . Improving paediatric medications: a prescription for Canadian children and youth. Paediatr Child Health. 2019;24:333&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6656949</ArticleId><ArticleId IdType="pubmed">31379437</ArticleId></ArticleIdList></Reference><Reference><Citation>Saitou H, Nakatani D, Myoui A, Kubota T, Ozono K.. Pediatric drug development in Japan: current issues and perspectives. Clin Pediatr Endocrinol. 2020;29:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6958521</ArticleId><ArticleId IdType="pubmed">32029968</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration . List of diseases for which FDA automatically grants a full waiver of pediatric studies. Available at: https://www.fda.gov/media/101440/download. Accessed December 16, 2021.</Citation></Reference><Reference><Citation>Al-Chalabi A, Calvo A, Chio A, Colville S, Ellis CM, Hardiman O, et al. . Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol. 2014;13:1108&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4197338</ArticleId><ArticleId IdType="pubmed">25300936</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, D&#x2019;Alfonso S, Corrado L, Canosa A, Moglia C, et al. . The multistep hypothesis of ALS revisited: the role of genetic mutations. Neurology 2018;91:e635&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6105040</ArticleId><ArticleId IdType="pubmed">30045958</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P, Al-Chalabi A.. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat Rev Neurol. 2011;7:603&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">21989245</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Mazzini L, Mora G.. Disease-modifying therapies in amyotrophic lateral sclerosis. Neuropharmacology 2020;167:107986.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062193</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Eijk RPA, Jones AR, Sproviero W, Shatunov A, Shaw PJ, Leigh PN, et al. . Meta-analysis of pharmacogenetic interactions in amyotrophic lateral sclerosis clinical trials. Neurology 2017;89:1915&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5664299</ArticleId><ArticleId IdType="pubmed">28978660</ArticleId></ArticleIdList></Reference><Reference><Citation>Armon C, Hardiman O.. The beginning of precision medicine in ALS? Treatment to fit the genes. Neurology 2017;89:1850&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">28978653</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, et al. . Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Iannaccone ST, Nelson LL. (2017). Spinal muscular atrophy clinical trials. in Spinal Muscul Atrophy (pp. 423-428)Elsevier Inc.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>